Biomarkers for precision medicine in bladder cancer
- 29 November 2016
- journal article
- review article
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 22 (2) , 207-213
Abstract
Bladder cancer (BC) is classified as non-muscle-invasive BC (NMIBC) or muscle-invasive BC (MIBC). Because the recurrence and mortality rates of BC are high, suitable biomarkers for early detection, evaluation of prognosis, and surveillance of drug responses are needed. Urinary markers simplify surveillance schedules and improve early detection of tumors, especially in NMIBC. Various markers have been identified at DNA, RNA, and protein levels with different sensitivities and specificities. Several biomarkers show a higher sensitivity than urinary cytology, but they are not accurate enough to replace it. In terms of prediction of clinical outcome and treatment response of BC, conventional clinical and pathological parameters are widely used, but the predictive ability of these parameters is limited; therefore, molecular biomarkers in this field are strongly desired. Molecular profiling using fluid and tissue is becoming more feasible with recent developments in next-generation sequencing technologies. Currently, these profiling methods are beginning to be used for early detection, prediction of prognosis, and drug sensitivity. Furthermore, several groups used transcriptome profiling to classify MIBC into various distinct subtypes, showing distinct clinical behaviors and responses to chemotherapy and immune checkpoint inhibitors. The aim of this review is to provide a summary of the most relevant biomarkers that have been investigated as diagnostic and prognostic indicators of BC.Keywords
This publication has 57 references indexed in Scilit:
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trialThe Lancet, 2016
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012International Journal of Cancer, 2014
- Intrinsic basal and luminal subtypes of muscle-invasive bladder cancerNature Reviews Urology, 2014
- Fluorescence-in-situ-hybridization in the Surveillance of Urothelial Cancers: Can Use of Cystoscopy or Ureteroscopy be Deferred?Asian Pacific Journal of Cancer Prevention, 2013
- Oncogenic FGFR3 gene fusions in bladder cancerHuman Molecular Genetics, 2012
- TCF21andPCDH17methylation: An innovative panel of biomarkers for a simultaneous detection of urological cancersEpigenetics, 2011
- UroVysion FISH test for detecting urothelial cancers: Meta-analysis of diagnostic accuracy and comparison with urinary cytology testingUrologic Oncology: Seminars and Original Investigations, 2008
- Evidence for the early onset of aberrant promoter methylation in urothelial carcinomaThe Journal of Pathology, 2006
- Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markersUrology, 2005
- Urinary interleukin-8 predicts the response of standard and low dose intravesical bacillus Calmette-Guerin (modified Danish 1331 strain) for superficial bladder cancer.2002